Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacitidine in Newly Diagnosed Higher-Risk MDS
NCT04401748Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of venetoclax in myelodysplastic syndrome (MDS), sponsored by AbbVie Inc.. Started Sep 2020; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04401748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401748.